Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.51 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMO | Q99835 | 3/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186677 | 0.91 | ALDH1A1 (0.58) | PTPN1ALDH1A1GRM1 | |
| SCHEMBL1124413 | 0.88 | DHODH (0.56) | DHODHPTPN1PTPN11PTPN2PTPN6 | |
| SCHEMBL1336628 | 0.77 | ALDH1A1 (0.79) | DHODHPTPN1PTPN11DEGS1ALDH1A1 | |
| SCHEMBL29360103 | 0.77 | ALDH1A1 (0.79) | DHODHPTPN1PTPN11DEGS1ALDH1A1 | |
| SCHEMBL1124341 | 0.75 | DHODH (0.63) | DHODHPTPN1PTPN11DEGS1ALDH1A1 | |
| SCHEMBL27624295 | 0.74 | PTPN1 (0.61) | PTPN1PTPN2DEGS1ALDH1A1 | |
| SCHEMBL1124246 | 0.72 | DHODH (1.00) | DHODHPTPN1PTPN11DEGS1ALDH1A1 | |
| SCHEMBL27624326 | 0.72 | ACMSD (0.47) | DHODHPTPN1ALDH1A1 | |
| SCHEMBL18132567 | 0.71 | ALDH1A1 (0.58) | DHODHALDH1A1SMO | |
| SCHEMBL8819957 | 0.71 | RAB9A (0.70) | ALDH1A1GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-1578741-B1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2011-07-13 | — | — | EP | disclosed |
| EP-2283898-A1 | Aromatic compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2011-02-16 | — | — | EP | disclosed |
| US-7365094-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2008-04-29 | — | — | US | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| EP-1581478-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1578741-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4SC AG (DE) | 2004-09-30 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
| WO-2004056797-A1 | AROMATIC COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | DHODH, SQOR, NDUFA5 | DHODH 1/4885PTPN1 1923/4885PTPN11 2233/4885 |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885PTPN1 4778/4885PTPN11 4824/4885 |
| US-20040192758-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | PPARG, PPARD, PPARA | DHODH 3023/4885PTPN1 741/4885PTPN11 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.